Actinium Pharmaceuticals, Inc. (ATNM) Key Metrics
ATNM valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $35.5M
- Enterprise value
- $2.0M
- P/E (TTM)
- 3.2
- Forward P/E
- 8.5
- PEG ratio
- —
- Price / sales
- 1.0 10-yr median 200.9
- Price / book
- 1.2 10-yr median 2.7
- EV / EBITDA
- 0.2
- Dividend yield
- —
- Beta
- 0.27
ATNM key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsATNM valuation Price multiples at each fiscal year-end price.
ATNM returns How much profit the business earns on the capital it uses.
ATNM per-share figures Results divided by the shares outstanding at year-end.
ATNM financial health Debt, liquidity and how easily interest is covered.
ATNM efficiency & capital use Working capital cycle and where the cash goes.
ATNM valuation history
ATNM returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ATNM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ATNM cash returned to shareholders
ATNM price vs earnings per share
ATNM key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $42.4M | $37.9M | $135.1M | $257.1M | $123.6M | $94.6M | — | — | — | — |
| Enterprise value | −$3.9M | −$33.4M | $60.6M | $150.8M | $46.1M | $31.8M | — | — | — | — |
| Price / sales | 471.4 | — | — | 249.6 | 108.1 | 152.2 | — | — | — | — |
| Price / book | 5.4 | 1.2 | 3.7 | 3.9 | 1.7 | 1.5 | — | — | — | — |
| Price / free cash flow | — | — | — | 31.1 | — | — | — | — | — | — |
| Price / operating cash flow | — | — | — | 29.7 | — | — | — | — | — | — |
| EV / sales | -43.1 | — | 748.0 | 146.4 | 40.3 | 51.1 | — | — | — | — |
| EV / free cash flow | — | — | — | 18.2 | — | — | — | — | — | — |
| Earnings yield | −79.9% | −100.9% | −36.1% | −12.8% | −20.0% | −23.5% | — | — | — | — |
| Free cash flow yield | −58.2% | −87.3% | −35.1% | 3.2% | −17.0% | −23.1% | — | — | — | — |
| Dividend yield | — | — | — | — | — | 0.0% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.5% | — | — | — | 0.0% | 0.0% | — | — | — | — |
| Share price at fiscal year-end | $1.36 | $1.26 | $5.08 | $10.65 | $6.01 | $7.80 | $6.53 | $11.61 | $19.91 | $26.25 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.04 | $0.06 | $0.05 | — | — | — | — |
| Earnings per share | −$1.09 | −$1.27 | −$1.83 | −$1.37 | −$1.20 | −$1.83 | — | — | — | — |
| Operating cash flow per share | −$0.79 | −$1.10 | −$1.78 | $0.36 | −$1.01 | −$1.78 | — | — | — | — |
| Free cash flow per share | −$0.79 | −$1.10 | −$1.78 | $0.34 | −$1.02 | −$1.80 | — | — | — | — |
| Cash per share | $1.54 | $2.42 | $2.88 | $4.51 | $3.78 | $5.24 | — | — | — | — |
| Book value per share | $0.25 | $1.09 | $1.37 | $2.75 | $3.58 | $5.05 | — | — | — | — |
| Tangible book value per share | $0.25 | $1.09 | $1.37 | $2.75 | $3.58 | $5.05 | — | — | — | — |
| Dividends per share | — | — | — | — | — | $0.00 | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.01 | $0.02 | $0.01 | $0.02 | — | — | — | — |
| Debt per share | $0.05 | $0.05 | $0.08 | $0.11 | $0.02 | $0.06 | — | — | — | — |
| Shares outstanding | 31.2M | 30.1M | 26.6M | 24.1M | 20.6M | 12.1M | — | — | — | — |
| Change in shares outstanding | +3.7% | +13.0% | +10.2% | +17.4% | +69.5% | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −167.0% | −110.6% | −94.9% | −47.2% | −36.7% | −66.3% | −302.9% | −210.4% | −167.9% | −121.7% |
| Return on assets (ROA) | −52.7% | −48.3% | −49.9% | −33.9% | −33.8% | −56.9% | −164.9% | −142.4% | −130.2% | −99.0% |
| Return on tangible assets | −65.5% | −49.7% | −59.9% | −28.9% | −30.8% | −33.5% | −187.6% | −158.9% | −145.1% | −108.0% |
| Free cash flow margin | — | — | — | 803.7% | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.7M | $1.6M | $2.1M | $2.6M | $310,000 | $738,000 | $1.4M | $262,593 | $15,916 | $300,683 |
| Cash & short-term investments | $48.0M | $72.9M | $76.7M | $108.9M | $77.8M | $63.6M | $9.3M | $13.7M | $17.4M | $20.5M |
| Net debt | −$46.3M | −$71.3M | −$74.6M | −$106.3M | −$77.5M | −$62.9M | −$7.8M | −$13.4M | −$17.4M | −$20.2M |
| Debt / equity | 0.22 | 0.05 | 0.06 | 0.04 | 0.00 | 0.01 | 0.25 | 0.03 | 0.00 | 0.02 |
| Debt / assets | 0.03 | 0.02 | 0.03 | 0.02 | 0.00 | 0.01 | 0.12 | 0.02 | 0.00 | 0.01 |
| Current ratio | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 | 1.89 | 2.36 | 3.82 | 4.95 |
| Quick ratio | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 | 1.89 | 2.36 | 3.82 | 4.95 |
| Interest coverage | — | — | — | -31.4 | -131.4 | — | — | -137.4 | — | — |
| Working capital | $41.4M | $66.4M | $69.8M | $100.3M | $72.9M | $60.2M | $4.7M | $8.3M | $13.2M | $17.9M |
| Invested capital | −$38.5M | −$38.6M | −$38.2M | −$39.8M | −$4.0M | −$1.6M | −$2.2M | −$4.6M | −$3.7M | −$2.2M |
| Tangible asset value | $7.8M | $32.8M | $36.4M | $66.5M | $73.5M | $61.3M | $5.6M | $8.8M | $13.7M | $18.0M |
| Net current asset value | $5.4M | $30.4M | $33.2M | $63.2M | $72.9M | $59.8M | $4.1M | $8.3M | $13.2M | $17.9M |
| Graham net-net per share | $0.13 | $0.96 | $1.19 | $2.53 | $3.45 | $4.82 | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | $1,000 | $1,269 | — | — | — |
| Share buybacks (net) | $207,000 | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 115.6% | — | 188.9% | 35.5% | 11.6% | 40.7% | — | — | — | — |
| Capex / operating cash flow | — | — | — | 4.2% | — | — | — | — | — | — |
| Capex / depreciation | 0.13 | 0.01 | 0.19 | 0.52 | 0.25 | 0.57 | 0.15 | 1.89 | 0.44 | 0.77 |
| Stock-based compensation / revenue | 10,211.1% | — | 4,743.2% | 271.4% | 148.1% | 201.6% | — | — | — | — |
| R&D / revenue | 23,471.1% | — | 47,740.7% | 2,246.1% | 1,530.3% | 2,586.0% | — | — | — | — |
| SG&A / revenue | 16,903.3% | — | 16,458.0% | 1,165.0% | 706.0% | 1,014.1% | — | — | — | — |
| Efficiency | ||||||||||
| Days payables outstanding | — | 3,492.7 | 4,177.4 | 4,089.9 | 3,439.3 | 3,649.2 | 4,523.3 | 37,651.0 | 28,857.0 | 13,345.2 |
| Payables turnover | — | 0.10 | 0.09 | 0.09 | 0.11 | 0.10 | 0.08 | 0.01 | 0.01 | 0.03 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | — | $7.8M | $9.0M | $7.8M | $4.9M | $4.5M | $5.2M | $5.2M | $4.4M | $2.8M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ATNM's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ATNM valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 3.2 and the forward P/E is 8.5. Actinium Pharmaceuticals earned a return on equity of −167.0% in fiscal 2025. It ended the year with $1.7 million of debt and $48.0 million in cash and short-term investments, a net cash position of $46.3 million. It returned $0.2 million to shareholders: $0 in dividends and $0.2 million in share buybacks.
See the ATNM income statement, the ATNM chart for price history, or the ATNM stock overview for the latest quote and news.
ATNM key metrics FAQ
What is Actinium Pharmaceuticals's P/E ratio?
Actinium Pharmaceuticals's trailing P/E ratio is 3.2 based on the last twelve months of earnings (as of October 17, 2026), and its forward P/E is 8.5. At the end of fiscal 2025 it was —.
What is Actinium Pharmaceuticals's return on equity?
Actinium Pharmaceuticals's return on equity (ROE) was −167.0% in fiscal 2025: net income of -$33.9 million on average shareholders' equity of $20.3 million.
How much debt does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals had total debt of $1.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.22 and more cash than debt.
Does Actinium Pharmaceuticals buy back its shares?
Yes. Actinium Pharmaceuticals spent $0.2 million on net share repurchases in fiscal 2025 Shares outstanding changed +3.7% over the year, to 31.2M..
What is Actinium Pharmaceuticals's free cash flow yield?
Actinium Pharmaceuticals generated -$24.7 million of free cash flow in fiscal 2025, a free cash flow yield of −58.2% on its market value at year-end ($42.4 million).
What is Actinium Pharmaceuticals's current ratio?
Actinium Pharmaceuticals's current ratio was 6.20 at the end of fiscal 2025: current assets were 6.20 times current liabilities.